Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin #3 [February 2018]

Product Code:
Publication Date:
February 2018

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA approval of Lynparza (olaparib; AstraZeneca) for patients with metastatic BC with BRCA gene mutation; Pfizer’s talazoparib EMBRACA Phase III data in patients with advanced or metastatic BC; as well as Syndax Pharmaceuticals announcing a collaboration with Genentech for a Phase Ib/II trial evaluating the combination of entinostat with Tecentriq (atezolizumab) in patients with second-line HR+/HER2- metastatic BC.

Business Questions:

  • How do KOLs view Lynparza’s approval?
  • What do KOLs consider Lynparza’s advantages/disadvantages?
  • According to KOLs, how will Lynparza be positioned?
  • How does talazoparib’s safety/efficacy compare to Lynparza?
  • Does talazoparib have any advantages over Lynparza?
  • What do KOLs think of combining entinostat with Tecentriq (atezolizumab)?
  • Which entinostat combination trial holds the most promise? Why?


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved